{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T05:46:16Z","timestamp":1793598376600,"version":"4.5.0"},"reference-count":21,"publisher":"American Medical Association (AMA)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"\n Importance<\/jats:title>\n Neuroendocrine neoplasms (NENs) are increasing in incidence; prevalence and at the same time, practice patterns have also evolved, impacting classification and survival of these malignant neoplasms. However, updated epidemiological data are lacking.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To define the epidemiological and survival trends of patients with NENs in the US.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n This cross-sectional study used data from the National Cancer Institute\u2019s Surveillance, Epidemiology, and End Results (SEER) program on NEN cases from 1975 to 2021. Analysis of project data was conducted between August 2023 and August 2024.<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n Annual age-adjusted incidence between 1975 and 2021, limited duration prevalence, and overall survival (OS) rates. Recent trends in survival were evaluated from 2000 to 2021 for the entire cohort as well as specific subgroups including distant stage gastrointestinal neuroendocrine tumors (NETs) and pancreatic NETs.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n In this analysis of 145\u202f447 NEN cases (mean [SD] age, 61.4 [14.7] years; 76\u202f057 female [52.4%]), the age-adjusted incidence rate increased 5.2-fold from 1975 (1.64 per 100\u202f000 persons; 95% CI, 1.43-1.87 per 100\u202f000 persons) to 2021 (8.52 per 100\u202f000 persons; 95% CI, 8.33-8.70 per 100\u202f000 persons) except for a dip in 2020 likely related to the COVID pandemic. This increase occurred across all sites, stages, and grades but was most marked for localized stage neoplasms (13-fold; 1975: 0.40 per 100\u202f000 persons [95% CI, 0.30-0.52]; 2021: 5.04 per 100\u202f000 persons [95% CI, 4.78-5.30]), well-differentiated neoplasms (53-fold; 1975: 0.04 per 100\u202f000 persons [95% CI, 0.02-0.09]; 2021: 2.30 per 100\u202f000 persons [95% CI, 2.13-2.48]), and neoplasms with the appendix (12-fold; 1975: 0.11 per 100\u202f000 persons [95% CI, 0.09-0.22]; 2021: 1.68 per 100\u202f000 persons [95% CI, 1.39-1.78]) or rectum (12-fold; 1975: 0.11 per 100\u202f000 persons [95% CI, 0.06-0.18]; 2021: 1.32 per 100\u202f000 persons [95% CI, 1.19-1.46]) as primary sites. Since 2000 (SEER 17 registry), the sites with the highest incidence rates included lung (1.49 per 100\u202f000 persons) and gastroenteropancreatic (GEP) NENs (6.1 per 100\u202f000 persons); within GEP NENs, small bowel (1.4 per 100\u202f000 persons) and pancreas (1.3 per 100\u202f000 persons) were the most common sites. The estimated 20-year limited duration prevalence of NENs in the US on January 1, 2021, was 248\u202f546 cases. OS for all NENs improved from the 2000-2006 period to the 2014-2021 period (hazard ratio [HR], 1.42; 95% CI, 1.38-1.45). In addition, other factors associated with survival included age, stage, grade, and primary site of origin. The median OS for all NENs was 11.8 years, and for distant-stage, well-differentiated neuroendocrine tumors it was 6.7 years with 10-year OS ranging from 17\u202f410 patients (15.4%) with rectum as primary site to 17\u202f505 patients (51.7%) with small bowel as primary site.<\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n Incidence and prevalence of NENs continue to rise driven by increased diagnosis of early stage disease. Survival for NENs has also improved over time.<\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2025.15798","type":"journal-article","created":{"date-parts":[[2025,6,24]],"date-time":"2025-06-24T11:00:52Z","timestamp":1750762852000},"page":"e2515798","source":"Crossref","is-referenced-by-count":124,"title":["Epidemiology of Neuroendocrine Neoplasms in the US"],"prefix":"10.1001","volume":"8","author":[{"given":"Arvind","family":"Dasari","sequence":"first","affiliation":[{"name":"Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katrine","family":"Wallace","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Biostatistics, University of Illinois, Chicago"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel M.","family":"Halperin","sequence":"additional","affiliation":[{"name":"Winship Cancer Institute, Emory University, Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Maxwell","sequence":"additional","affiliation":[{"name":"Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pamela","family":"Kunz","sequence":"additional","affiliation":[{"name":"Department of Medicine, Section of Medical Oncology, Yale School of Medicine and Yale Cancer Center, New Haven, Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simron","family":"Singh","sequence":"additional","affiliation":[{"name":"University of Toronto, Toronto, Ontario, Canada"},{"name":"Sunnybrook Odette Cancer Center, Sunnybrook Health Sciences Center, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beth","family":"Chasen","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, The University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James C.","family":"Yao","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2025,6,24]]},"reference":[{"issue":"10","key":"zoi250502r2","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1001\/jamaoncol.2017.0589","article-title":"Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States.","volume":"3","author":"Dasari","year":"2017","journal-title":"JAMA Oncol"},{"issue":"1","key":"zoi250502r3","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1200\/JCO.2016.69.2780","article-title":"Telotristat ethyl, a tryptophan hydroxylase inhibitor for the treatment of carcinoid syndrome.","volume":"35","author":"Kulke","year":"2017","journal-title":"J Clin Oncol"},{"issue":"7","key":"zoi250502r4","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1200\/JCO.22.01013","article-title":"Randomized study of temozolomide or temozolomide and capecitabine in patients with advanced pancreatic neuroendocrine tumors (ECOG-ACRIN E2211).","volume":"41","author":"Kunz","year":"2023","journal-title":"J Clin Oncol"},{"issue":"10022","key":"zoi250502r5","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1016\/S0140-6736(15)00817-X","article-title":"Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study.","volume":"387","author":"Yao","year":"2016","journal-title":"Lancet"},{"issue":"9","key":"zoi250502r6","doi-asserted-by":"publisher","first-page":"1588","DOI":"10.1007\/s00259-017-3728-y","article-title":"Guideline for PET\/CT imaging of neuroendocrine neoplasms with 68Ga-DOTA-conjugated somatostatin receptor targeting peptides and 18F-DOPA.","volume":"44","author":"Bozkurt","year":"2017","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"12","key":"zoi250502r7","doi-asserted-by":"publisher","first-page":"1752","DOI":"10.1016\/S1470-2045(21)00572-6","article-title":"177Lu-Dotatate plus long-acting octreotide versus high-dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trial.","volume":"22","author":"Strosberg","year":"2021","journal-title":"Lancet Oncol"},{"issue":"2","key":"zoi250502r8","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1056\/NEJMoa1607427","article-title":"Phase 3 Trial of 177Lu-dotatate for midgut neuroendocrine tumors.","volume":"376","author":"Strosberg","year":"2017","journal-title":"N Engl J Med"},{"issue":"1","key":"zoi250502r9","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1007\/s12022-022-09708-2","article-title":"Overview of the 2022 WHO classification of neuroendocrine neoplasms.","volume":"33","author":"Rindi","year":"2022","journal-title":"Endocr Pathol"},{"issue":"18","key":"zoi250502r14","doi-asserted-by":"publisher","first-page":"3063","DOI":"10.1200\/JCO.2007.15.4377","article-title":"One hundred years after \u201ccarcinoid\u201d: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States.","volume":"26","author":"Yao","year":"2008","journal-title":"J Clin Oncol"},{"issue":"14","key":"zoi250502r16","doi-asserted-by":"publisher","first-page":"1378","DOI":"10.1056\/NEJMsr1905447","article-title":"Epidemiologic signatures in cancer.","volume":"381","author":"Welch","year":"2019","journal-title":"N Engl J Med"},{"issue":"2","key":"zoi250502r17","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/S1470-2045(22)00750-1","article-title":"Hemicolectomy versus appendectomy for patients with appendiceal neuroendocrine tumours 1-2 cm in size: a retrospective, Europe-wide, pooled cohort study.","volume":"24","author":"Nesti","year":"2023","journal-title":"Lancet Oncol"},{"issue":"59","key":"zoi250502r18","doi-asserted-by":"publisher","first-page":"99541","DOI":"10.18632\/oncotarget.20362","article-title":"Regional lymph node involvement and outcomes in appendiceal neuroendocrine tumors: a SEER database analysis.","volume":"8","author":"Mehrvarz Sarshekeh","year":"2017","journal-title":"Oncotarget"},{"issue":"32","key":"zoi250502r20","doi-asserted-by":"publisher","first-page":"5049","DOI":"10.1200\/JCO.23.01529","article-title":"Systemic therapy for tumor control in metastatic well-differentiated gastroenteropancreatic neuroendocrine tumors: ASCO guideline.","volume":"41","author":"Del Rivero","year":"2023","journal-title":"J Clin Oncol"},{"issue":"7","key":"zoi250502r21","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1097\/MPA.0000000000001597","article-title":"The North American Neuroendocrine Tumor Society consensus guidelines for surveillance and medical management of pancreatic neuroendocrine tumors.","volume":"49","author":"Halfdanarson","year":"2020","journal-title":"Pancreas"},{"key":"zoi250502r13","volume-title":"International Classification of Diseases for Oncology","author":"Fritz","year":"2000","edition":"3rd ed"},{"key":"zoi250502r19"},{"key":"zoi250502r1","unstructured":"National Cancer Institute. Surveillance, Epidemiology, and End Results Program. Accessed December 2, 2024. https:\/\/seer.cancer.gov\/"},{"key":"zoi250502r10","unstructured":"Surveillance, Epidemiology, and End Results (SEER) Program. SEER*Stat Database: Incidence - SEER Research Data, 8 Registries, Nov 2023 Sub (1975-2021) - Linked To County Attributes - Time Dependent (1990-2022) Income\/Rurality, 1969-2022 Counties. April 2024 based on the November 2023 submission. Accessed December 2, 2024. https:\/\/seer.cancer.gov\/data\/"},{"key":"zoi250502r11","unstructured":"Surveillance, Epidemiology, and End Results (SEER) Program. SEER*Stat Database: Mortality - All COD, Aggregated With State, Total U.S. (1969-2022) <Katrina\/Rita Population Adjustment>, National Cancer Institute, DCCPS, Surveillance Research Program. April 2024. Accessed December 2, 2024. https:\/\/seer.cancer.gov\/mortality\/"},{"key":"zoi250502r12","unstructured":"Surveillance, Epidemiology, and End Results (SEER) Program. SEER*Stat Database: Populations - Total U.S. (1969-2022) <Katrina\/Rita Adjustment> - Linked To County Attributes - Total U.S., 1969-2022 Counties. Released March 2024. Accessed December 2, 2024. https:\/\/seer.cancer.gov\/popdata\/"},{"key":"zoi250502r15","unstructured":"ProjPrev version 1.0.4. June 2017. Data Modeling Branch, National Cancer Institute. https:\/\/surveillance.cancer.gov\/projprev\/"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2835520\/dasari_2025_oi_250502_1762182178.2679.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T16:01:12Z","timestamp":1762358472000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2835520"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,24]]},"references-count":21,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6,2]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2025.15798","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,24]]}}}